Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Masimo ( (MASI) ) has shared an update.
On August 5, 2025, Masimo Corporation announced its financial results for the second quarter of 2025, reporting a GAAP revenue of $371 million, an 8% growth, and a non-GAAP revenue of $370 million, a 7% growth on a constant currency basis. The company’s non-GAAP net income per diluted share grew by 46% compared to the previous year. CEO Katie Szyman highlighted the company’s strong performance and strategic focus on expanding its leadership in pulse oximetry and implementing effective tariff mitigation measures, which have positively impacted its growth strategy and market position.
The most recent analyst rating on (MASI) stock is a Buy with a $170.00 price target. To see the full list of analyst forecasts on Masimo stock, see the MASI Stock Forecast page.
Spark’s Take on MASI Stock
According to Spark, TipRanks’ AI Analyst, MASI is a Neutral.
Masimo’s overall stock score of 63 reflects a mix of strong strategic moves and ongoing challenges. The earnings call was particularly positive, highlighting resilience and strategic focus, which significantly boosts the score. However, financial and valuation metrics, as well as technical analysis, present challenges that temper the overall assessment.
To see Spark’s full report on MASI stock, click here.
More about Masimo
Masimo Corporation operates in the healthcare industry, specializing in advanced monitoring technologies and pulse oximetry. The company focuses on increasing its market share in key global markets and advanced monitoring categories.
Average Trading Volume: 644,787
Technical Sentiment Signal: Buy
Current Market Cap: $8.35B
See more insights into MASI stock on TipRanks’ Stock Analysis page.